| ★ |  GDF2026 - Controlled Correspondences: Minimizing Rejections, Maximizing Results | U.S. Food and Drug Administration @us_fda | 37 | Estados Unidos | |
| 5 |  GDF2026 - Closing Remarks | U.S. Food and Drug Administration @us_fda | 595 | Estados Unidos | 93 |
| 4 |  GDF2026 - Recent Trends in Pharmaceutical Freeze-Drying and Control Strategies | U.S. Food and Drug Administration @us_fda | 304 | Estados Unidos | 93 |
| 7 |  GDF2026 - Q&A Discussion Panel Four and Day One Closing | U.S. Food and Drug Administration @us_fda | 187 | Estados Unidos | 93 |
| 20 |  GDF2026 - Overview of the FDA Product-Specific Guidance (PSG) Program | U.S. Food and Drug Administration @us_fda | 166 | Estados Unidos | 92 |
| 8 |  GDF2026 - Q&A Discussion Panel Two | U.S. Food and Drug Administration @us_fda | 136 | Estados Unidos | 93 |
| 12 |  GDF2026 - Best Practices for Safety Assessment of Nitrosamines in Generic Drugs | U.S. Food and Drug Administration @us_fda | 127 | Estados Unidos | 93 |
| 6 |  GDF2026 - Pre-Abbreviated New Drug Application (ANDA) Meetings for Complex Drug Products | U.S. Food and Drug Administration @us_fda | 101 | Estados Unidos | 93 |
| 16 |  GDF2026 - Office of Pharmaceutical Quality (OPQ) Keynote | U.S. Food and Drug Administration @us_fda | 101 | Estados Unidos | 93 |
| 18 |  GDF2026 - Complex Drug Products – Quality Considerations for Generic Oligonucleotides | U.S. Food and Drug Administration @us_fda | 86 | Estados Unidos | 93 |
| 15 |  GDF2026 - Q&A Discussion Panel Three | U.S. Food and Drug Administration @us_fda | 72 | Estados Unidos | 93 |
| 1 |  GDF2026 - Product-Specific Guidances (PSGs) in Action – Key Lessons and Common Questions | U.S. Food and Drug Administration @us_fda | 58 | Estados Unidos | 94 |
| 2 |  GDF2026 - Decoding PSGs for Complex Non-Oral Generics | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 94 |
| 17 |  GDF2026 - Prioritization Requests: Prioritizing Original and Supplemental ANDAs | U.S. Food and Drug Administration @us_fda | 49 | Estados Unidos | 93 |
| 9 |  GDF2026 - Using FDA’s Inactive Ingredient Database (IID): Best Practices and Considerations | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 93 |
| 10 |  GDF2026 - Common Bioequivalence (BE) Study Design Deficiencies and How to Avoid Them | U.S. Food and Drug Administration @us_fda | 47 | Estados Unidos | 93 |
| 3 |  GDF2026 - Factors that Can Facilitate Assessment of Type II Drug Master Files (DMFs) | U.S. Food and Drug Administration @us_fda | 43 | Estados Unidos | 93 |
| 13 |  GDF2026 - Suitability Petitions | U.S. Food and Drug Administration @us_fda | 41 | Estados Unidos | 93 |
| 14 |  GDF2026 - Orange Book: How Drug Product Listings are Added, Updated, and Maintained | U.S. Food and Drug Administration @us_fda | 39 | Estados Unidos | 93 |
| 19 |  GDF2026 - Q&A Discussion Panel Five | U.S. Food and Drug Administration @us_fda | 29 | Estados Unidos | 92 |
| 11 |  GDF2026 - Proactive Strategies to Avoid Major Filing Deficiencies and Other Filing Stumbling Blocks | U.S. Food and Drug Administration @us_fda | 25 | Estados Unidos | 93 |